Page results
-
Nine Covid-19 research studies are already taking place at UCLH and the Trust is processing more than 30 study proposals as research efforts around the virus and pandemic are ramped up.
-
This information will give you an overview of BCG immunotherapy, how it is given and side effects it may cause.
-
RESPOND – Information for healthcare professionals and services working with asylum seekers
-
CAMLIS is the Royal London Hospital for Integrated Medicine (RLHIM) Complementary and Alternative Medicine Information and Library Service and is situated on the ground floor of the hospital.
-
Having proton beam therapy under general anaesthetic: information for children aged 1- 4 patient information.
-
Having proton beam therapy under general anaesthetic: information for children aged 5-8 patient information
-
UCLH has recruited the first participant for a new UK based study for Parkinson’s Disease (PD). The ASPro-PD study is testing whether treatment with a drug called ambroxol is associated with an improvement in motor and non-motor function compared with placebo.
-
UCLH is continuing to scale up the number of services that offer Advice & Guidance, as well as identifying various improvements within the existing Advice & Guidance service. Over the last few months, UCLH has introduced 5 new specialties to the service, with additional specialties due to go live shortly.
-
UCLH and UCL are at the forefront of Women’s Health care and research – across areas including reproductive health, maternity, breast care, care for newborns, gynaecological care, and cancer.
-
UCLH is celebrating the delivery of its 1,000th respiratory syncytial virus (RSV) vaccine to pregnant women, following the rollout of the new national programme in September.
File results
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer
-
FOI/2022/0194 - Drug treatment for lung cancer
-
FOI/2022/0199 - Trust postal service and patient communication
-
FOI/2022/0200 - IT budget/ chatbots
-
FOI/2022/0205 - Spending on communication activities